Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03952325
Title Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Patients With HER2 Negative MBC (CONTESSA TRIO)
Acronym CONTESSA TRIO
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Odonate Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Sarah Cannon Research Institute - Florida Cancer Specialists Fort Myers Florida 33901 United States Details
Florida Cancer Specialists and Research Institute Saint Petersburg Florida 33705 United States Details
Florida Cancer Specialists and Research Institute - Panhandle Region Tallahassee Florida 32308 United States Details
Florida Cancer Specialists and Research Institute West Palm Beach Florida 33401 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
New York Cancer and Blood Specialists East Setauket New York 11733 United States Details
West Cancer Center Germantown Tennessee 38138 United States Details
Texas Oncology - Baylor Charles A. Sammons Cancer Center Dallas Texas 75246 United States Details
Virginia Oncology Associates Norfolk Virginia 23502 United States Details
Asan Medical Center Seoul Korea, Republic of Details
John Hopkins Singapore International Medical Centre Singapore Singapore Details
National Cancer Centre Singapore Singapore Singapore Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field